Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer

Table 1 Average survival time (day) of rat (n = 0, mean ± SD)

Group	Injection on d 1	Injection on d 3	Injection on d 5	Injection on d 7
Physiologic saline control	10.7 ± 1.5	-	-	-
Blank vector control	11.4 ± 1.3	-	-
IL-2 gene therapy	25.0 ± 2.5b	23.5 ± 2.0b	18.3 ± 2.4b	12.0 ± 1.8
IL-12 gene therapy	39.0 ± 4.8b	32.0 ± 3.9b	23.0 ± 2.5b	19.4 ± 2.1a
IL-12-IL-2 fused gene therapy	53.3 ± 3.7c	49.3 ± 4.2c	31.0 ± 2.1c	24.3 ± 1.4c

^aP < 0.05 and

^bP < 0.01 vs physiologic saline control and blank vector control;

^cP < 0.05 vs IL-2 group or IL-12 group.

Table 2 Determination of serum hIL-2 or mIL-12 3 d after administration of IL gene (ng/mL)

Group	HIL-2	MIL-12
Physiologic saline control	< 0.8	< 0.8
Blank vector control	< 0.8	< 0.8
IL-2 gene therapy	19.4 ± 1.8	< 0.8
IL-12 gene therapy	< 0.8	22 ± 2.5
IL-12-IL-2fused gene therapy	18.5 ± 2.4	20.5 ± 2.5

Table 3 Determination of serum hIL-2 and mIL-12 on fused gene group (ng/mL)

Group	HIL-2	MIL-12
Control	< 0.8	< 0.8
On d 3 after therapy	18.5 ± 2.4	20.5 ± 2.5
On d 7 after therapy	10.2 ± 2.5	11.5 ± 2.5
One mo after therapy	5.3 ± 1.2	6.2 ± 1.4
Two mo after therapy	< 0.8	< 0.8